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Case Report
A Case of Simpson-Golabi-Behmel Syndrome
Presenting with Cutaneous Findings
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Description

Simpson-Golabi-Behmel syndrome is a rare, X-linked recessive syndrome associated with
mutations in the genes encoding glypican 3 (GPC3). The majority of cases have been
described in pediatric males, with those affected showing manifestations of overgrowth,
congenital heart defects, and increased incidence of neoplasia. Due to the X-linked nature
of this disorder, penetrance is not well understood in female cases. Very few cases of female
presentations of Simpson-Golabi-Behmel syndrome have been described, and this case
highlights that there may be an association between mutated GPC3 carrier status and other
cancers. We present a case of GPC3 gene mutation suggestive of Simpson-Golabi-Behmel
syndrome in an adult female patient, diagnosed based on genetic testing performed due to
a diagnosis of sebaceous carcinoma.
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Introduction

Simpson-Golabi-Behmel syndrome is a rare,
X-linked recessive syndrome associated with
mutations in the genes encoding glypican 3
(GPC3).1 The majority of cases have been described in pediatric males, with those affected
showing manifestations of overgrowth, congenital heart defects, and increased incidence
of neoplasia. Due to the X-linked nature of this
disorder, penetrance is not well understood in
female cases. Very few cases of female presentations of Simpson-Golabi-Behmel syndrome
have been described, and this case highlights
that there may be an association between mutated GPC3 carrier status and other cancers.
We present a case of GPC3 gene mutation consistent with Simpson-Golabi-Behmel syndrome
in an adult female patient.

Case Presentation

A 65-year-old female with a past medical history of hypertension and hyperlipidemia originally
presented with a 0.5 cm fleshy papule on her

right lateral eyebrow that had been present for
approximately 2 months. She denied any associated systemic symptoms or other dermatological complaints at that time. The lesion was
biopsied and diagnosed as a sebaceous carcinoma. Immunohistochemical (IHC) staining of the
biopsy specimen, a renal ultrasound and colonoscopy were ordered. IHC staining was negative for any microsatellite instability for MSH-2,
MSH-6, MLH-1 or PMS-2, and the colonoscopy
was unremarkable. A complete renal ultrasound
revealed a mild prominence of the renal pelvis
and infundibulum with no significant hydronephrosis. A computed tomography (CT) of the
abdomen was performed, and the patient was
diagnosed with low-grade papillary urothelial
carcinoma of the right renal pelvis and subsequently underwent a right radical nephroureterectomy. Due to evidence of malignancy in
her ureter with associated hematuria, a follow-up cystoscopy was planned. The cystoscopy found additional evidence of low-grade papillary carcinoma of the bladder. The patient was
referred to a genetic counselor due to a con-
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cern for possible Muir Torre syndrome (MTS).
Due to an intact expression of all 4 mismatch
repair proteins associated with MTS, it was
reassuring that the patient did not have Lynch
syndrome. The Mayo Muir-Torre syndrome risk
score was calculated with our patient receiving
a score of 1, corresponding to a relatively low
likelihood of having Muir-Torre/Lynch syndrome. Due to a recent history of renal cancer,
our patient elected to undergo genetic testing.
Our patient tested positive for a heterozygous
mutation in the glypican-3 protein (GPC3) gene
c.595>T (p.Arg199*). Germline mutations for
MLH-1, MSH-2, MSH-6, PMS-2 and PTEN were
negative. Mutations in GPC3 are a well-established cause of Simpson-Golabi-Behmel syndrome (SGBS) and pointed to the diagnosis
of SGBS in our patient. The patient was counseled to continue regular follow-up with dermatology, oncology and urology.

Discussion

Simpson-Golabi-Behmel syndrome (SGBS) is
a rare, X-linked overgrowth/multiple congenital abnormality syndrome first reported by
Simpson et al. in 1975.1 Only 2 genes have been
implicated in the development of SGBS. The
first and most well-established gene causing
SGBS encodes GPC3, a glycosylphosphatidylinositol-linked cell surface heparan sulfate
proteoglycan, that maps to Xp26.2 Similarly,
GPC4 is located adjacent to GPC3 and belongs
to a family of glypicans, which encode heparan
sulfate proteoglycans.3 GPC3 and GPC4 are believed to play a key role in cell growth and division in embryonic mesodermal tissues and may
modulate insulin-like growth factor 2 (IGF2)
action.2,3 Diagnosis guidelines have not been
established, but previous cases are diagnosed
based on suggestive findings in a patient with a
hemizygous mutation involving GPC3 that may
also involve GPC4.4 GPC3 expression has been
linked with urothelial carcinomas, especially
high-grade tumors.5
Due to its X-linked nature, the majority of cases
that have been discussed are in male patients
and detected at an early age. The characteristics of SGBS include pre- and post-natal
overgrowth, typical facies with prominent eyes
and macroglossia, macrocephaly, organomegaly, other anomalies including diaphragmatic
hernias, renal defects, gastrointestinal defects,
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skeletal anomalies and an increased tumor risk
with a mild/moderate intellectual deficiency.1,6 SGBS is known to be associated with an
increased risk of embryonal tumors, including
Wilms tumor, hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular
carcinoma.7 It is not known if other cancers are
associated with mutations in GPC3.
Females that inherit the mutation of GPC3
tend to be asymptomatic carriers. However,
with random X-chromosome inactivation, individuals may have phenotypic manifestations
of SGBS. There have been few female cases
described in the literature.2,3,6,8-11 Penetrance
of SGBS in female carriers is unknown. In the
8 reported female cases of SGBS in the literature, none have presented with sebaceous
carcinoma or renal cancer. The previous cases
described were found in infant females due to
a concern for multiple congenital abnormality
syndromes. In the first case presented by Punnett in 1994, the patient was initially diagnosed
with Beckwith-Wiedemann syndrome, which
was changed to SGBS after genetic testing
revealed a balanced X;1 translocation at Xq2527.8 Similarly, the case described by Pilia et al.
was due to a balanced X;16 translocation.2 Yano
et al. described a female who was identified
after her brothers were diagnosed with SGBS.6
Vaisfeld et al., Shimojima et al., Mujezinovic et
al. and Schirwani et al. are later cases of infant
females who have demonstrated significant
features of SGBS.3,9-11
To the best of our knowledge, there have been
no other cases of SGBS reported to date that
have presented in an adult female with sebaceous carcinoma or with a clinical history of
renal cancer. Challenges include an accurate diagnosis of SGBS in a female due to its X-linked
recessive inheritance as well as a lack of established criteria for diagnosis. Due to the paucity
of female cases described in the literature,
multiple questions are raised. Is this syndrome
more prevalent in females than previously
recognized? Is there a greater association with
other malignancies than previously described
that may not be elucidated until later in life?
This case points to a possible association of
increased risk of cancers, including sebaceous
adenocarcinoma and renal cancer with a carrier
status of a mutated G3PC gene. While many
questions remain unanswered, asking them
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highlights the importance of awareness of this
syndrome and careful examination of those
females found to be carriers.

Abbreviations

SGBS: Simpson-Golabi-Behmel Syndrome
GPC3: Glypican 3
GPC4: Glypican 4
IHC: Immunohistochemical
MSH-2: mutS homolog 2
MSH-6: mutS homolog 6
MLH-1: mutL homolog 1
PMS-2: PMS1 homolog 2
CT: Computed tomography
MTS: Muir-Torre Syndrome
PTEN: phosphotase and tensin homolog
IGF2: Insulin-like growth factor
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